BRPI0408299A - inibidores de catepsina s - Google Patents

inibidores de catepsina s

Info

Publication number
BRPI0408299A
BRPI0408299A BRPI0408299-0A BRPI0408299A BRPI0408299A BR PI0408299 A BRPI0408299 A BR PI0408299A BR PI0408299 A BRPI0408299 A BR PI0408299A BR PI0408299 A BRPI0408299 A BR PI0408299A
Authority
BR
Brazil
Prior art keywords
inhibitors
compounds
cathepsin
cathepsin inhibitors
relates
Prior art date
Application number
BRPI0408299-0A
Other languages
English (en)
Inventor
Eugene R Hickey
Weimen Liu
Sanxing Sun
Yancey David Ward
Erick Richard Roush Young
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BRPI0408299A publication Critical patent/BRPI0408299A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

"INIBIDORES DE CATEPSINA S". Esta invenção refere-se a compostos de peptidila de fórmulas (I) e (II) ativos como inibidores de catepsina S, uma protease da cisteína. Os compostos são inibidores seletivos reversíveis da catepsina S são, portanto, úteis no tratamento de doenças auto-imunes e outras doenças. A invenção também se refere a processos para preparação desses compostos e a composições farmacêuticas que compreendem os mesmos.
BRPI0408299-0A 2003-03-13 2004-03-03 inibidores de catepsina s BRPI0408299A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45423903P 2003-03-13 2003-03-13
PCT/US2004/006554 WO2004083182A1 (en) 2003-03-13 2004-03-03 Cathepsin s inhibitors

Publications (1)

Publication Number Publication Date
BRPI0408299A true BRPI0408299A (pt) 2006-03-07

Family

ID=33029865

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408299-0A BRPI0408299A (pt) 2003-03-13 2004-03-03 inibidores de catepsina s

Country Status (16)

Country Link
US (1) US7326719B2 (pt)
EP (1) EP1606258A1 (pt)
JP (1) JP4455506B2 (pt)
KR (1) KR20050109553A (pt)
CN (1) CN100400511C (pt)
AR (1) AR043563A1 (pt)
AU (1) AU2004221860A1 (pt)
BR (1) BRPI0408299A (pt)
CA (1) CA2518728A1 (pt)
MX (1) MXPA05008240A (pt)
NZ (1) NZ542905A (pt)
PE (1) PE20050312A1 (pt)
RU (1) RU2005131502A (pt)
TW (1) TW200509919A (pt)
WO (1) WO2004083182A1 (pt)
ZA (1) ZA200505418B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146658A1 (en) 2003-09-18 2008-10-30 Schering Ag Haloalkyl containing compounds as cysteine protease inhibitors
JP2007509961A (ja) * 2003-10-30 2007-04-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ジペプチド類似体合成
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
US8163735B2 (en) 2004-12-02 2012-04-24 Virobay, Inc. Sulfonamide compounds as cysteine protease inhibitors
BRPI0609695A2 (pt) 2005-03-21 2011-10-18 Applera Corp composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença e uma paciente sofrendo uma terapia
WO2006102535A2 (en) 2005-03-22 2006-09-28 Celera Genomics Sulfonyl containing compounds as cysteine protease inhibitors
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
CA2664878A1 (en) 2006-10-04 2008-04-10 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
WO2009054454A1 (ja) * 2007-10-24 2009-04-30 National University Corporation Tokyo Medical And Dental University カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
DE102009028929A1 (de) * 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
WO2011109470A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Heteroaryl nitrile compounds useful as inhibitors of cathepsin-s
CN106715472A (zh) * 2014-09-18 2017-05-24 豪夫迈·罗氏有限公司 用于监测组织蛋白酶s抑制的方法
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4234014A1 (en) * 2022-02-28 2023-08-30 Insusense ApS Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776718A (en) 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
GB9723407D0 (en) 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
PL202226B1 (pl) 1997-11-05 2009-06-30 Novartis Ag Nitryl dipeptydowy, jego zastosowanie lecznicze i zawierająca go kompozycja farmaceutyczna
EP1155010A1 (en) 1999-02-20 2001-11-21 AstraZeneca AB Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
AU779177B2 (en) 1999-03-15 2005-01-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6492362B1 (en) 1999-09-16 2002-12-10 Axys Pharmaceuticals, Inc. Compounds and compositions as cathepsin S inhibitors
US6982263B2 (en) * 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases

Also Published As

Publication number Publication date
AR043563A1 (es) 2005-08-03
EP1606258A1 (en) 2005-12-21
NZ542905A (en) 2009-04-30
MXPA05008240A (es) 2005-10-05
RU2005131502A (ru) 2006-08-27
CA2518728A1 (en) 2004-09-30
AU2004221860A1 (en) 2004-09-30
WO2004083182A1 (en) 2004-09-30
US20040180886A1 (en) 2004-09-16
TW200509919A (en) 2005-03-16
ZA200505418B (en) 2007-01-31
CN100400511C (zh) 2008-07-09
PE20050312A1 (es) 2005-06-14
US7326719B2 (en) 2008-02-05
JP4455506B2 (ja) 2010-04-21
KR20050109553A (ko) 2005-11-21
JP2006519768A (ja) 2006-08-31
CN1761652A (zh) 2006-04-19

Similar Documents

Publication Publication Date Title
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
SE0201980D0 (sv) Novel compounds
BRPI0408299A (pt) inibidores de catepsina s
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NO20064584L (no) Tetrahydropyridoindolderivater
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
SE0201976D0 (sv) Novel compounds
SE0301700D0 (sv) Novel compounds
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
ATE433447T1 (de) Pyrimiidinverbindungen
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
TW200514772A (en) Novel tetrahydropyridine derivatives
SE0101932D0 (sv) Pharmaceutical combinations
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
EA201201550A1 (ru) Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
DK1694660T3 (da) Fremgangsmåde til fremstilling af vandfri og hydrerede aktive farmaceutiske bestanddele (API's); stabile farmaceutiske sammensætninger fremstillet af disse og anvendelser af disse sammensætninger
PT1407763E (pt) Composicoes contendo um acido organico cosmeticamente activo e um produto a base de uma leguminosa
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
SE0203712D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A ,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2174 DE 04/09/2012.